Stay current with the latest news and events from TriSalus
TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today the appointment of Trevor McCaw as Chief Commercial Officer, a new position within TriSalus reporting directly to TriSalus CEO, Mary Szela. McCaw will play a central role in integrating the Company’s therapeutics and innovative drug delivery systems to provide a total solution for patients. McCaw was most recently President and Chief Commercial Officer of Clerio Vision.
TriSalus Life Sciences (TriSalus), an emerging immuno-oncology Company committed to transforming outcomes for patients with solid tumors, announced today the appointment of Steven Katz, M.D., as its Chief Medical Officer. Katz will oversee the Company’s clinical development strategy as it seeks to overcome poor outcomes in the treatment of solid tumors by combining TriSalus’ proprietary, FDA-cleared intravascular, regional drug delivery technology with immuno-oncology therapeutics. Katz has served as the Company’s Chief Medical Advisor and as Chairman of its Scientific Advisory Board since 2018.
TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate
TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today its therapeutic clinical development strategy following the successful acquisition of SD-101, an investigational IND-ready immunotherapy, from (Dynavax) Technologies on August 3, 2020.
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for liver and pancreatic tumors, today announced that they have entered into an asset purchase agreement under which TriSalus has purchased SD-101, a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide, which has been studied in advanced cutaneous melanoma, and is currently in clinical trials for high risk Stage II/III breast cancer. Purchased assets include SD-101-related Intellectual Property, clinical data, regulatory filings, and inventory.
TriSalus Life Sciences (TriSalus), a company committed to transforming outcomes for patients with solid tumors, announces the appointment of Scott Davie to the role of Chief Technology Officer, deepening the company’s leadership capabilities as it builds an integrated therapeutic/drug delivery portfolio. As chief technology officer, Davie will oversee research and development of the company’s intravascular infusion systems powered by its proprietary Pressure Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, as well as operations, pre-clinical execution, and management of the IP portfolio. A 25-year veteran of the medical device industry across multiple industry segments, Davie also will serve as site lead for the company’s Westminster, CO facility and report to the company’s President and Chief Executive Officer, Mary Szela.
TriSalus Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the appointment of Rajesh B. Mistry as Chief Financial Officer. Mr. Mistry joins TriSalus with a wide spectrum of healthcare experience, spanning pharmaceuticals, biotech, medical devices, and healthcare services. His background extends from VC-backed start-ups to publicly traded, multinational corporations where he drove M&A, corporate finance and capital raising efforts.
TriSalus Life Sciences and Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology That Can Enhance Drug Delivery into Pancreatic Tumors
Study to Evaluate the Pressure-Enabled Drug Delivery™ Approach Combined with Standard of Care Chemotherapy to Enable Deep Tumor Penetration and Minimize Dose-Limiting Toxicity.
TriSalus™ Life Sciences, a company committed to developing comprehensive solid tumor solutions, today announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its intravascular, tumor-directed proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach with standard of care systemic chemotherapy.
TriSalus Life Sciences Launches the New TriNav™ Infusion System, an Innovative Solution Designed to Overcome Infusion Barriers Within Solid Tumors
TriSalus™ Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav™ Infusion System (“TriNav”). Powered by its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, TriNav is designed to help overcome the infusion barriers that limit therapeutic uptake in solid tumors, including hepatocellular carcinoma (HCC) and liver metastases.
TriSalus Life Sciences’ Surefire® Spark™ Infusion System (TriNav™) Receives CMS Approval for Transitional Pass-Through Payment Status Designed to Improve Therapeutic Distribution and Penetration in Solid Tumors
TriSalus™ Life Sciences (formerly Surefire Medical Inc.), a company committed to treating cancer at its origins, today announced that the Centers for Medicare & Medicaid Services (CMS) granted approval for transitional pass-through (TPT) payment for its Surefire® Spark™ Infusion System.
TriSalus™ Life Sciences announced the election of Diane Parks and Yongxin Han to its Board of Directors, effective immediately.
The appointment of two new members of the company’s board of directors further advances the transformation into an oncology platform and brings expertise in the development and commercialization of drug and drug delivery technology.
TriSalus Life Sciences Forms World-Class Scientific Advisory Board to Accelerate Advancement of Strategy to Deliver Therapeutics to Solid Tumors
TriSalus™ Life Sciences, an oncology company focused on overcoming infusion barriers to improve patient outcomes, today announced the creation of a world-class scientific advisory board (SAB) to support advancement of the company’s strategy to deliver therapeutics more effectively into solid tumors.
TriSalus Life Sciences’ Pressure-Enabled Drug Delivery™ (PEDD™) Increases Penetration and Antitumor Activity of Anti-CEA CAR-T in Mouse Model of Liver Metastases
A preclinical trial to be presented at the annual meeting of the American Association of Immunologists (AAI) demonstrates that administering anti–carcinoembryonic antigen (anti-CEA) CAR-T to liver metastases using high delivery pressure in an animal model simulating TriSalus™ Life Sciences’ innovative Pressure-Enabled Drug Delivery™ (PEDD™) significantly increased penetration and antitumor activity when compared with standard low-pressure (LP) delivery.